Huang, Xin http://orcid.org/0000-0001-6778-8849
Park, Kyoung-mi
Gontarz, Paul
Zhang, Bo http://orcid.org/0000-0003-2962-5314
Pan, Joshua
McKenzie, Zachary
Fischer, Laura A.
Dong, Chen http://orcid.org/0000-0002-5405-5715
Dietmann, Sabine
Xing, Xiaoyun http://orcid.org/0000-0002-1045-1775
Shliaha, Pavel V.
Yang, Jihong http://orcid.org/0000-0002-2753-0939
Li, Dan http://orcid.org/0000-0002-6332-1093
Ding, Junjun http://orcid.org/0000-0002-9936-882X
Lungjangwa, Tenzin
Mitalipova, Maya
Khan, Shafqat A.
Imsoonthornruksa, Sumeth
Jensen, Nick http://orcid.org/0000-0002-1177-3418
Wang, Ting http://orcid.org/0000-0002-6800-242X
Kadoch, Cigall http://orcid.org/0000-0002-4058-5985
Jaenisch, Rudolf http://orcid.org/0000-0002-2540-7099
Wang, Jianlong http://orcid.org/0000-0002-1317-6457
Theunissen, Thorold W. http://orcid.org/0000-0001-6943-7858
Article History
Received: 19 April 2021
Accepted: 12 July 2021
First Online: 26 August 2021
Competing interests
: R.J. is a cofounder of Fate Therapeutics, Fulcrum Therapeutics, and Omega Therapeutics, and an advisor to Dewpoint Therapeutics. C.K. is the Scientific Founder, fiduciary Board of Directors member, Scientific Advisory Board member, shareholder, and consultant for Foghorn Therapeutics. The remaining authors declare no competing interests.